Lessons learned from acute and late scaffold failures in the ABSORB EXTEND trial
EuroIntervention 2014;10:449-457 published online ahead of print January 2014. DOI: 10.4244/EIJV10I4A78
Yuki Ishibashi1, MD, PhD; Yoshinobu Onuma1, MD; Takashi Muramatsu1, MD, PhD; Shimpei Nakatani1, MD; Javaid Iqbal1, MRCP, PhD; Hector M. Garcia-Garcia1, MD, PhD; Antonio L. Bartorelli2, MD; Robert Whitbourn3, MD; Alexander Abizaid4, MD, PhD; Patrick W. Serruys1, MD, PhD; on behalf of the ABSORB EXTEND Investigators
1. Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; 2. Centro Cardiologico Monzino, IRCCS, University of Milan, Milan, Italy; 3. St Vincent’s Hospital, Fitzroy, Victoria, Australia; 4. Instituto de Cardiologia Dante Pazzanese,
Aims: Bioresorbable scaffolds are increasingly used in patients with coronary artery disease undergoing percutaneous coronary interventions. ABSORB EXTEND is an ongoing study that will re
